UT Southwestern-linked CNS disease drug developer Taysha has filed to raise up to $100m in an IPO, just weeks after its $96m series B.
Taysha Gene Therapies, a US-based gene therapy developer based on research at University of Texas (UT) Southwestern, filed for a $100m initial public offering on Wednesday.
Founded in 2019 in partnership with UT Southwestern Medical Center, and launched in April this year, Taysha is developing gene therapies for monogenic diseases of the central nervous system (CNS).
The company plans to initiate a phase 1/2 clinical trial for a drug candidate dubbed TSHA-101 for a rare genetic disorder…
